<p><i>In vitro</i> efficacy of Maraviroc in PBMC cultures. The histogram represents the percentage of viral inhibition (p24 production pg/ml) in presence of Maraviroc, AMD3100 and AZT at different concentrations, considering the untreated as 100. Mean values of at least 3 experiments for each isolate are shown. Error bars indicating inter-experimental standard deviations are shown. Maraviroc median IC<sub>50</sub> and IC<sub>90</sub> values of 3 different experiments are also shown. The False Positive Rate (FPR) values are based on the V3 sequences and calculated with Geno2Pheno algorithm. The phenotypic tropism was evaluated on astroglioma U87MG-CD4<sup>+</sup>-CCR5<sup>+</sup>−/CXCR4<sup>+</sup>-expressing cells (DR: R5<sup>+</sup>X4; D: ...
<p>Shown are the CD4+ T cell counts and the viral loads over time. A) CD4+ T cell counts and B) Vira...
Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the...
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study,...
<p><i>In vitro</i> efficacy of Maraviroc in MDM cultures. The bars represents the percentage of vira...
<p>The bars represents the percentage of HIV-1 DNA copies and p24 values (normalized per 10<sup>6</s...
<p>The bars represents the percentages of HIV-1 isolate replication in PBMC cultures infected with 1...
(A) Change in viral load (◊ dashed line) and CD4 (▪ solid line) for participant 3, who received mara...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>In each graph, the percentages of inhibition relative to the extent of virus replication in the n...
<p>The bars represents the percentages of HIV-1 isolate replication in MDM cultures infected with 8,...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>MAGIC-5 cells were infected with pseudotyped viruses in the absence or presence of 1 µM maraviroc...
Abstract Objective Few data are available about the efficacy of maraviroc (MVC) during routine use. ...
<p>Shown are the CD4+ T cell counts and the viral loads over time. A) CD4+ T cell counts and B) Vira...
Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the...
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study,...
<p><i>In vitro</i> efficacy of Maraviroc in MDM cultures. The bars represents the percentage of vira...
<p>The bars represents the percentage of HIV-1 DNA copies and p24 values (normalized per 10<sup>6</s...
<p>The bars represents the percentages of HIV-1 isolate replication in PBMC cultures infected with 1...
(A) Change in viral load (◊ dashed line) and CD4 (▪ solid line) for participant 3, who received mara...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>In each graph, the percentages of inhibition relative to the extent of virus replication in the n...
<p>The bars represents the percentages of HIV-1 isolate replication in MDM cultures infected with 8,...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>MAGIC-5 cells were infected with pseudotyped viruses in the absence or presence of 1 µM maraviroc...
Abstract Objective Few data are available about the efficacy of maraviroc (MVC) during routine use. ...
<p>Shown are the CD4+ T cell counts and the viral loads over time. A) CD4+ T cell counts and B) Vira...
Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the...
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study,...